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Introduction 
With the introduction of high dose therapy/ autologous
stem cell transplantation as well as novel agents (up-front),
most patients with multiple myeloma (MM) achieve a tran-
sient remission; however, the vast majority relapse within a
median of 3 years from diagnosis.1 Thus, long-term follow-up
studies in the setting of high dose therapy/ autologous stem
cell transplantation show that only a small fraction of MM
patients (6-18%) remain relapse free for 10 years or more, and
these patients are now considered as being operationally
cured.2-4 Interestingly, this operational cure is not restricted to
patients in complete response, since those who revert to hav-
ing a monoclonal gammopathy of undetermined significance
(MGUS)-like profile may also achieve long-term disease con-
trol (LTDC), despite persistence of a residual M-component.4
Recent clinical and molecular data suggest that some features
may help to identify this group of LTDC-MM patients such as
an evolving smoldering pattern, a gene expression profile sig-
nature of MGUS and the CD2 molecular subtype.5,6
Collectively, these findings suggest that in addition to anti-
myeloma therapy, other factors may play a critical role in dis-
ease control.
For decades, increasing evidence has shown that the
immune system is dysfunctional and impaired in active MM.7-
10 Accordingly, B-cell precursors and normal plasma cells are
compromised, and immune paresis is also a consistent finding
in newly-diagnosed MM patients.11 In turn, effector cells such
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Multiple myeloma remains largely incurable. However, a few patients experience more than 10 years of relapse-
free survival and can be considered as operationally cured. Interestingly, long-term disease control in multiple
myeloma is not restricted to patients with a complete response, since some patients revert to having a profile of
monoclonal gammopathy of undetermined significance. We compared the distribution of multiple compartments
of lymphocytes and dendritic cells in the bone marrow and peripheral blood of multiple myeloma patients with
long-term disease control (n=28), patients with newly diagnosed monoclonal gammopathy of undetermined sig-
nificance (n=23), patients with symptomatic multiple myeloma (n=23), and age-matched healthy adults (n=10).
Similarly to the patients with monoclonal gammopathy of undetermined significance and symptomatic multiple
myeloma, patients with long-term disease control showed an expansion of cytotoxic CD8+ T cells and natural
killer cells. However, the numbers of bone marrow T-regulatory cells were lower in patients with long-term dis-
ease control than in those with symptomatic multiple myeloma. It is noteworthy that B cells were depleted in
patients with monoclonal gammopathy of undetermined significance and in those with symptomatic multiple
myeloma, but recovered in both the bone marrow and peripheral blood of patients with long-term disease control,
due to an increase in normal bone marrow B-cell precursors and plasma cells, as well as pre-germinal center periph-
eral blood B cells. The number of bone marrow dendritic cells and tissue macrophages differed significantly
between patients with long-term disease control and those with symptomatic multiple myeloma, with a trend to
cell count recovering in the former group of patients towards levels similar to those found in healthy adults. In
summary, our results indicate that multiple myeloma patients with long-term disease control have a constellation
of unique immune changes favoring both immune cytotoxicity and recovery of B-cell production and homing, sug-
gesting improved immune surveillance.
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ABSTRACT
as natural killer (NK) cells and cytotoxic CD8+ T cells are
expanded in both the bone marrow (BM) and peripheral
blood (PB), but they are unable to control disease progres-
sion, suggesting a marked immunosuppressive microenvi-
ronment.12,13 Moreover, dendritic cells (DC) have also been
reported to be altered in MM, with reductions in circulating
myeloid DC (m-DC) and plasmacytoid DC (p-DC), lower
expression of co-stimulatory molecules and impaired
induction of allogeneic T-cell responses.14-16
Since these immune defects are invariably present in
active MM, we hypothesized that the immune system
may play a critical role in LTDC-MM patients. To explore
this possibility, in the present study we compared the dis-
tribution of many different subsets of T- B - and NK-lym-
phocytes and DC in both the BM and PB of MM patients
who achieved long term disease control (LTDC-MM) ver-
sus the distributions in patients with newly diagnosed
MGUS and symptomatic MM, as well as in healthy adults
of similar age.
Design and Methods
Patients, controls and samples
A total of 74 patients with plasma cell disorders were prospec-
tively studied. The group under investigation was composed of
LTDC-MM patients (n=28), defined as either: (i) MM patients
achieving complete response after up-front therapy and remaining
relapse free for >5 years (n=11), or (ii) patients achieving  a near
complete response or partial response and remaining progression-
free for ≥3 years without therapy (n=17) (MGUS-like profile). As
controls, newly-diagnosed MGUS patients (n=23) and sympto-
matic MM patients (n=23), as well as age-matched healthy adult
volunteers (n=10) undergoing orthopedic surgery, were studied.
All samples from controls and patients were collected after
informed consent had been given by each individual, according to
the local ethical committee requirements and the Helsinki
Declaration. Most LTDC-MM patients (90%) were enrolled in the
GEM 2000 protocol and, therefore, received six induction cycles of
VBMCP/VBAD followed by high-dose therapy/autologous stem
cell transplantation and maintenance with interferon/prednisone.
At the time of the present study, 85% of these patients were off
any anti-myeloma therapy for >4 years. The median time from
diagnosis was 9 years (range, 5 to 20 years). The study was con-
ducted on paired BM and PB samples collected at the same time
for each individual. Overall, a total of 168 samples were obtained
with the following distribution per group: LTDC-MM (median age
of 70 years; range, 52 to 85 years), 56 samples; MGUS (median age
of 71 years; range, 43 to 93 years), 46 samples; symptomatic MM
(median age of 74 years; range, 50 to 89 years), 46 samples and;
healthy adults (median age of 64 years; range, 40 to 89 years), 20
samples.
Multiparametric flow cytometry immunophenotypic
studies
EDTA-anticoagulated fresh BM and PB samples (approximately
1 mL) from each subject were immunophenotyped during the first
24 h, using an eight-color direct immunofluorescence technique
previously described in detail.17,18 The monoclonal antibody com-
binations – Pacific blue (PacB), fluorescein isothiocyanate (FITC),
Pacific orange (PacO), phycoerythrin (PE), peridinin chlorophyll
protein-cyanin 5 (PerCPCy5), PE-cyanin 7(PECy7), allophyco-
cyanin (APC), Alexafluor 700 (AF700) or APCH7 used with the
aim of quantifying and characterizing B cells, T cells, NK cells and
DC, as well as their subsets, were as follows: (i) CD4, CD45,
CD45RA, CD127, CD8, CD25, CD56, CD3; (ii) HLADR, CD45,
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Figure 1. Immunophenotypic identification of
regulatory T cells (Treg) and their distribution in
PB and BM samples from MM patients with
long-term disease control (LTDC-MM) (n=28)
versus both newly-diagnosed MGUS patients
(MGUS; n=23), symptomatic MM patients (MM-
s; n=23) and age-matched healthy adults (HA;
n=10). In panel (A), the gating strategy used for
the identification of CD4+ CD25hi CD127lo Treg
within gated CD4+ T-lymphocytes, is illustrated.
Panel (B) shows the distribution of Treg cell
numbers in PB (right) and BM (left) and of
LTDC-MM* patients versus HA, MGUS and MM-
s. P≤0.05 versus LTDC-MM (Mann-Whitney U-
test).
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CD16, CD33, CD34, CD117, CD123, CD14; (iii) CD20, CD45,
CD62L, CXCR4, CD19, CD27, CD10+TCRγδ, CD38; (iv) CD20,
CD45, surface membrane immunoglobulin (SmIg)G, SmIgA,
CD19, CD27, SmIgM, CD38; CD45, CD38, CD56, CD138,
CD19, CyK+TCRγδ and Cyλ. Based on these combinations the
following populations of lymphocytes were identified in PB and
BM samples: total CD3+ T cells and their major CD3+/CD4+,
CD3+/CD8+ and TCRγδ+ cell subsets plus CD4+/CD25+/CD127-
regulatory T cells (Treg) (Figure 1A), in addition to total CD3-
/CD56+ NK cells, CD14+ monocytes and DC subsets (e.g. circulat-
ing HLA-DR+/CD16+ tissue macrophages, HLA-DR+/CD123+ p-
DC and HLA-DR+/CD33+ m-DC) (Figure 2A), as well as total
CD19+ B-cells and their maturation-associated subsets in PB -
immature (CD10+, CD27-, CD38+), naïve (CD10-, CD27-, CD38-)
and memory (CD10-, CD27+, CD38-) B-lymphocytes plus plas-
mablasts/plasma cells (CD27++, CD38++, CD10-) - and in BM - B-cell
precursors (CD19+, CD38+, CD45lo), naïve plus memory
(CD19+/CD38-/CD45+) B-lymphocytes and normal plasma cells
(CD138+/CD38+/CD19+/CD45+/CD56-) - (Figure 3A), as described
previously.17,19-21 In all cases, data were acquired in a FACSCanto II
flow cytometer (BDB) using the FACSDiva software (version 6.1,
BDB) for ≥ 106 leukocytes/tube using the EuroFlow instrument
setup data acquisition standard operating procedures.22 INFINI-
CYT software (Cytognos SL, Salamanca, Spain) was used for the
data analysis.
Statistical methods
The number of PB cell populations was recorded as absolute
number of cells/μL while BM cell populations were described as
percentages of all BM nucleated cells, after correcting for the levels
of plasma cell infiltration. The median and mean values (and their
standard deviation) and range were calculated for all the parame-
ters. The Mann-Whitney U test was used to evaluate the statistical
significance of differences observed between groups. The SPSS
software package (version 15.0, SPSS, Inc., Chicago, IL, USA), was
used for all statistical analyses.
Results
Distribution of distinct populations of effector 
cells and regulatory T cells in peripheral blood 
and bone marrow
The CD4+/CD8+ ratio was significantly lower, both in
the PB and BM, of LTDC-MM patients than in healthy
adults (P≤0.0001), patients with MGUS (P≤0.05) or symp-
tomatic MM patients (P≤0.008) (Figure 4A). This was
mainly due to an increase in the number of CD8+ T cells
in LTDC-MM, MGUS and symptomatic MM patients
with respect to healthy adults, the level of CD4+ T-cells
remaining unaltered. LTDC-MM patients also showed
increased numbers of CD56lo NK-cells in PB versus healthy
adults (P=0.01) (Figure 4B). The number of total T-lym-
phocytes and the TCRγδ+ T cells was similar among
groups (data not shown). In addition, the number of Treg
cells in the BM of LTDC-MM patients was within the
normal range (similar to that found in healthy adults) but
significantly lower than that in symptomatic MM
patients (P=0.04) (Figure 1B).
Distribution of B-cell populations in peripheral blood
and bone marrow
The total PB and BM B-cell counts from LTDC-MM
patients were within the normal range (similar to those
found in healthy adults), but significantly higher than
those observed in the PB of MGUS patients (P=0.04) and
in the PB and BM of symptomatic MM patients (P=0.004
and P=0.005, respectively) (Figure 3B). A similar pattern
was also found for the distribution of B-cell precursors in
the BM of LTDC-MM patients versus symptomatic MM
patients (P=0.002) (Figure 3C). In depth analysis of the dif-
ferent subsets of PB B cells (immature, naïve and memory
B-lymphocytes plus plasmablasts/plasma cells) showed
that the pre-germinal center cell subsets (e.g. immature
and naïve B-lymphocytes) were present in LTDC-MM
patients at similar values to those in healthy adults, while
increased with respect to those in MGUS patients (P=0.01
and P=0.006, respectively) and symptomatic MM patients
(P=0.01 and P=0.0001, respectively). Conversely, no differ-
ences were detected in PB for memory B cells or plas-
mablasts/plasma cells among the three groups (Figure 3C).
Despite this, the number of terminally differentiated nor-
mal BM plasma cells was significantly increased in LTDC-
MM versus symptomatic MM patients (P=0.002), with val-
ues similar to those in MGUS patients (P=0.6), but still
reduced compared to those in healthy adults (P=0.03).
Distribution of circulating tissue macrophages and 
dendritic cells in peripheral blood and bone marrow
The overall DC counts in PB and BM were similar in
LTDC-MM, MGUS, and symptomatic MM  patients and
in healthy adults. However, a more detailed analysis of the
distinct subsets of DC and tissue macrophages showed a
significantly different composition of this cell compart-
ment in LTDC-MM versus symptomatic MM patients
(Figure 2B,C). LTDC-MM patients had higher percentages
of p-DC (P=0.05) in both PB and BM, as well as of m-DC
(P=0.01) in PB; by contrast, the number of tissue
macrophages was decreased in both the BM (P=0.06) and
PB (P=0.02) of these patients. Overall, these differences
were associated with a recovery of the normal distribution
of PB DC and tissue macrophages in LTDC-MM patients
towards levels similar to those found in healthy adults
(P>0.05). Nevertheless, differences were still noted
between LTDC-MM patients and healthy adults for BM
tissue macrophages (P=0.03) and p-DC (P=0.03).
Distribution of lymphoid cells and dendritic cells 
in multiple myeloma patients with long-term disease
control according to depth of response and duration 
of remission
Persistent minimal residual disease (MRD) was detected
by highly sensitive multiparametric flow cytometry in the
BM of 20/28 (70%) LTDC-MM patients, while the other
eight cases (30%) were MRD-negative with a sensitivity
of 10-5. These eight patients were considered as being in
immunophenotypic complete remission, while the first 20
MRD-positive patients were considered as showing an
MGUS-profile by immunophenotyping, due to the coexis-
tence of normal and residual myelomatous plasma cells.
Interestingly, when we compared the distribution of T, B,
NK and DC in these two groups of LTDC-MM, no signif-
icant differences were observed. The only relevant finding
was a significantly higher number of normal plasma cells,
both in the BM (P=0.01) and PB (P=0.04) of MRD-negative
versus MRD-positive patients. In addition, we stratified
LTDC-MM patients into those achieving a complete
response (n=11) versus those with a near complete
response or partial response (MGUS-profile; n=17). As for
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the former comparison, no major differences were found
in the distribution of PB T, B, NK and DC between the
groups (Table 2).
Finally, we investigated whether the duration of remis-
sion in LTDC-MM patients was associated with specific
changes in the immune system, by comparing patients
with ≥ 10 years disease control (n=7) versus patients with
5-10 years follow-up (n=21). Our results showed that the
former cohort had higher total T-cell counts in the PB
(P=0.004), including both the CD4+ (P=0.001) and CD8+
(P=0.008) subsets, naïve B cells (P=0.04), and m-DC
(P=0.03) (Table 2).
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Figure 2. Identification of
different dendritic cell sub-
sets (A) and distribution of
total dendritic cells and
their subsets in PB (B) and
BM (C) from MM patients
with long-term disease
control (LTDC-MM) (n=28)
versus patients with newly-
diagnosed MGUS (MGUS;
n=23), patients with symp-
tomatic MM (MM-s; n=23)
and age-matched healthy
adults (HA; n=10). *P≤
0.05 versus LTDC-MM
(Mann-Whitney U-test).
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Discussion
Despite the fact that until recently MM was considered
incurable, the introduction of high dose therapy/ autolo-
gous stem cell transplantation and novel drugs has made it
possible for a small fraction of patients to attain long-term
(≥5 years) disease control even in the absence of a com-
plete response, after reverting to having an MGUS-like
profile. The underlying mechanisms leading to disease
suppression in these patients are largely unknown,
although immune surveillance has been hypothesized to
play a critical role.
In this exploratory study, we analyzed the distribution
of the most representative populations of different func-
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Figure 3. Immunophenotypic
identification of the different
B-cell subsets in bone mar-
row and peripheral blood (A),
and the distribution of total
CD19+ B-cells (B) and their
subsets (panel C) in MM
patients with long-term dis-
ease control (LTDC-MM)
(n=28) versus patients with
newly-diagnosed MGUS
(MGUS; n=23), patients with
symptomatic MM (MM-s;
n=23) and age-matched
healthy adults (HA; n=10).
*P≤0.05, **P≤0.005,
***P≤0.001 versus LTDC-
MM (Mann-Whitney U-test).
A
B
C
-1E2 0 1E2 1E3 1E4 1E5
HA (n=10) MGUS (n=23) MM-s (n=23) LTDC-MM (n=28)
HA (n=10) MGUS (n=23) MM-s (n=23) LTDC-MM (n=28)
1E5
1E4
1E3
0
400
300
200
100
0
2.5
2.0
1.5
1.0
0.5
0.0
2.5
2.0
1.5
1.0
0.5
0.0
300
250
200
150
100
50
0
10
8
6
4
2
0
1E5
1E4
1E3
0
-1E3
CD45 - PacB
CD
38
 - 
FI
TC
CD
38
 - 
AF
70
0
N.
 o
f C
D1
9+
ce
lls
/μ
L 
of
 P
B
%
 o
f B
M
 C
D1
9+
ce
lls
%
 o
f B
M
 C
D1
9+
ce
lls
%
 o
f P
B 
CD
19
+
ce
lls
/μ
L
N.
 o
f C
D1
9+
ce
lls
/n
uc
le
at
ed
 B
M
 c
el
ls
0 1E3 1E4 1E5
CD27 - APC
Bone marrow
Bone marrow
B-precursors Normal-
plasma cells 
HA
MGUS
MM-s
LTDC-MM
Immature Naive Memory Plasmablasts
Bone marrow
**P< vs. LTDC-MM
Bone marrow
Normal plasma cells (CD138+/CD38+/CD19+/ CD45+/CD56-)
B-cell precursors
(CD19+, CD38+, CD45lo)
Immature B-cells
(CD10+, CD27-, CD38+)
Memory B-cells
(CD10-, CD27+, CD38-)
Plasmablasts/plasma cells 
(CD27++, CD38++, CD10-)
Naive B-cells
(CD10-, CD27-, CD38-)
Naive + memory
B-lymphocytes
(CD19+/CD38-/CD45+)
Peripheral blood
Peripheral blood
Peripheral blood
tional compartments of the immune system in MM
patients achieving long-term disease control. Similarly to
what has been previously described for symptomatic
MM,12,23-25 effector CD8+ T and NK cells were also found to
be increased in LTDC-MM. Recruitment of cytotoxic cells
into the tumor microenvironment could reflect a host
immune surveillance mechanism to control tumor growth,
which would be inefficient in newly-diagnosed sympto-
matic patients. In this regard, an expansion of Treg cells
potentially mediating immune suppression may be crucial
for myelomatous plasma cells to evade immune surveil-
lance, and the main obstacle for successful immunothera-
py (e.g. idiotypic vaccination in MM).26,27 Interestingly, our
study showed that LTDC-MM patients have lower num-
bers of Treg cells than do symptomatic MM patients, par-
ticularly in the BM. Despite a large body of evidence that
points to increased numbers and a functionally effective
status of Treg cells in both hematologic and non-hemato-
logic malignancies,28 the results reported in MM are con-
troversial, which is probably related to the different
methodologies and techniques used to identify the cells.29-
31 In our study, Treg cells were identified based on their
unique CD4+, CD25hi, CD127-/lo phenotype (Figure 1A),
which has been shown to be directly correlated to the
major CD4+, FoxP3+ Treg subset.32,33 It can, therefore, be
hypothesized that in LTDC-MM patients, the reduction of
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Figure 4. Distribution of T-cell subsets and NK cells in the PB and BM of
MM patients with long-term disease control (LTDC-MM) (n=28) compared
to both newly-diagnosed MGUS (MGUS; n=23) and symptomatic MM
(MM-s; n=23) patients and age-matched healthy adults (HA; n=10). In
panel (A), the major CD4+ and CD8+ T-cell subsets together with the
CD4/CD8 T-cell ratio are displayed for PB (upper quadrants) and BM
samples (lower quadrants). Panel (B) shows the distribution of NK cells
in PB (right) and BM (left) of HA, and patients with MGUS, MM-s, or LTDC-
MM is displayed.  *P≤ 0.05 and **P≤ 0.001 vs. LTDC-MM (Mann-Whitney
U-test).
Table 1. Distribution of different T-, B-, NK- and DC cell populations in the PB and BM of MM patients with long-term disease control (LTDC-MM)
(n=28) versus age-matched healthy adults (HA) (n=10) and newly diagnosed MGUS (n=23) and symptomatic-multiple myeloma (MM-s) (n=23)
patients.
HA MGUS MM-s LTDC-MM HA MGUS MM-s LTDC-MM  
PB PB BM BM
T cells 864±433 1271±565 1108±637 1266±979 9±3 11±6 12±7 12±6
CD4+ 574±284 642±227 593±343 519±245 5±2 6±3 7±4 5±2
CD8+ 252±161* 544±423 464±416 688±774 3±1* 5±4 6±3 7±4
T- γδ 26±19 43±41 34±27 41±45 0.32±.27 0.45±.3 0.33±.22 0.4±.27
Treg 41±16 47±18 42±26 37±16 0.5±.16 0.48±.29 0.57±.33 0.40±.24
NK cells 141±84 249±204 227±141 230±134 1.2±.7 2.1±2 2.7±2 2.2±2
B cells 142±101 107±70* 87±73** 164±104 3±2 2±1 1.2±1** 3±2
B precursors - - - - 0.7±.3 0.6±.6 0.2±.2** 0.7±1.1
Immature 8±5 4±3* 4±4* 9±7 - - - -
Naïve 95±95 66±44* 50±40*** 119±78 - - - -
Memory 37±22 35±28 31±38 34±29 - - - -
Normal-PC 2±2 1.4±2 1.3±1.4 1.2±1 0.32±.25* 0.17±.20* 0.04±.05** 0.19±.28
DC 45±14 68±43 56±40 59±27 0.50±.37 0.39±.25 0.6±.42 0.52±.28
m-DC 10±5 16±16 9±10** 13±8 - - - -
TiMas 31±12 46±39 42±38 40±22 0.28±.35 0.26±.23 0.55±.51 0.39±.28
p-DC 4±1 6±4 5±7 5±3 0.21±.06* 0.13±.06 0.12±.10 0.15±.10
Peripheral blood results are expressed as mean number of cells/ mL ± one standard deviation; bone marrow numbers reflect percentages of cells from all nucleated bone marrow
cells ± one standard deviation. *P≤ 0.05, ** P≤0.005, ***P≤0.001 vs. LTDC-MM respectively (Mann-Whitney U-test). PC: plasma cells; TiMas: tissue macrophages.
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Treg in the BM microenvironment could promote a
stronger cytotoxic effect of the expanded CD8+ T- and
NK-lymphocytes, favoring local immune surveillance. If
this hypothesis holds true, a recovery of B-cell response
and antibody production should also be seen in LTDC-
MM patients. 
Disrupted B-cell lymphopoiesis and antibody secretion
(e.g. immune paresis), with compromised production and
BM homing of normal plasma cells, is a hallmark of symp-
tomatic MM.11,34-36 In LTDC-MM, we observed a replenish-
ment of early B-cell subsets in the BM (B-cell precursors),
translating into increased numbers of circulating immature
and naïve B-cells in PB, and a recovery of end-stage normal
plasma cells in the BM. Recovery of B-cell production in
the BM could be related to decreased competition
between clonal plasma cells and normal plasma cells (as
well as B-cell precursors), for a limited number of SDF-1-
associated BM niches.36 In line with this hypothesis, we
found that circulating PB plasmablasts/plasma cells from
LTDC-MM patients displayed lower expression of the
CXCR4 surface chemokine receptor than those from
patients with symptomatic MM, similar to the expression
in healthy adults (data not shown); these observations could
indicate that newborn plasmablasts/plasma cells can more
easily migrate and home to the appropriate BM niches.
Collectively, these findings would support the hypothesis
that the regeneration of B-cell precursors in the BM could
drive the shift towards increased numbers of newly gener-
ated B cells in PB, which would also eventually increase
the homing and number of normal plasma cells in the BM.
This B-cell replenishment loop occurring after therapy36
and particularly its long-term maintenance could be a  sin-
gular feature of LTDC-MM. Further investigations about
the specific mechanisms involved in the maintained B-cell
recovery are, therefore, required.
We also investigated the DC compartment in both the
BM and PB of LTDC-MM patients. Overall, our results
showed that LTDC-MM patients recovered normal counts
of different subsets of DC in PB; however, a reduction in
p-DC together with an increase in tissue circulating
macrophages was still noted (versus healthy adults), but
such alterations were much less pronounced than in
patients with symptomatic MM. It is noteworthy that the
partial normalization of DC counts and the distribution of
these cells described here for LTDC-MM patients are sim-
ilar to those reported by Kovarova et al.37 in MM patients
who remained in remission for 6 months after autologous
stem cell transplantation. 
Since patients who are relapse-free for ≥10 years are
considered to be operationally cured,4 we further investi-
gated the immune profile of this specific subgroup of
LTDC-MM patients. Interestingly, these patients had sig-
nificantly increased numbers of CD8+ and CD4+ T cells,
naïve B cells and m-DC, not only compared to LTDC-MM
patients with 5-10 years follow-up, but also compared to
healthy adults. These findings suggest that the immune
profile of LTDC-MM patients does not reflect a simple
overall recovered immune status identical to that of
healthy adults of similar age, but rather an unique
“immune signature”.
In summary, our results indicate that LTDC-MM
patients have a constellation of unique immune changes,
consisting of increased numbers of effector cytotoxic
CD8+ T-lymphocytes and NK cells, B cells, normal plasma
cells and also DC, with simultaneous reduction in Treg
cells potentially favoring both the action of cytotoxic cells,
and the recovery of B-cell production and homing of nor-
mal plasma cells into the BM. Altogether, these unique
features of patients with LTDC-MM suggest that the
patients have improved immune surveillance, which
deserves further investigations to dissect the specific
underlying molecular and functional mechanisms
involved.
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